Company
Endo Operations
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
18
5 still marketed
Novel approvals
5
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Aveed approved Mar 5, 2014
- Sumavel Dosepro new use Nov 26, 2013
- Valstar Preservative Free new use Aug 2, 2013
- Fortesta approved Dec 29, 2010
- Sumavel Dosepro approved Jul 15, 2009
- Supprelin La approved OrphanMay 3, 2007
- Opana Er approved Jun 22, 2006
- Megace Es approved Jul 5, 2005
- Nascobal approved Jan 31, 2005
- Vantas approved Oct 12, 2004
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
- Supprelin La Histrelin Acetate · 2007
- Testim Testosterone · 2002
- Aveed Testosterone Undecanoate · 2014
- Edex Alprostadil · 1997
- Valstar Preservative Free Valrubicin · 1998
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.